Literature DB >> 32646803

Sleep disturbances and the At Risk Mental State: A systematic review and meta-analysis.

Latoya Clarke1, Katharine Chisholm2, Francesco P Cappuccio3, Nicole K Y Tang4, Michelle A Miller3, Farah Elahi3, Andrew D Thompson3.   

Abstract

AIMS: To synthesise and investigate how sleep disturbances relate to psychotic symptoms, functioning and Quality of Life (QoL) in At Risk Mental State (ARMS) youth.
METHOD: A comprehensive search of six databases (MEDLINE, PsycINFO, Embase, CINAHL, Web of Science and CENTRAL) was conducted. Eligible studies provided data on sleep disturbances or disorders in ARMS patients.
RESULTS: Sixteen studies met the inclusion criteria (n = 1962 ARMS patients) including 7 cross-sectional studies, 2 RCT's and 7 cohort studies. Narrative synthesis revealed that self-reported sleep (e.g., general disturbances, fragmented night time sleep and nightmares) was poorer among ARMS patients compared to healthy controls. In the limited studies (n = 4) including objective measurements of sleep disturbances, ARMS patients experienced higher levels of movement during sleep, more daytime naps and increased sleep latency compared to controls. Furthermore, sleep disturbances were associated with attenuated psychotic symptoms and functional outcomes cross-sectionally and longitudinally. Only one study investigated the relationship between sleep and QoL. The exploratory meta-analysis revealed a significant difference in self-reported sleep disturbances measured by the PSQI (mean difference in score: 3.30 (95% CI 1.87, 4.74), p < 0.00001) and SIPS (mean difference in score: 1.58 (95% CI 0.80, 2.35), p < 0.00001) of ARMS patients compared to control groups.
CONCLUSIONS: ARMS individuals report impaired sleep quality and reduced sleep quantity compared to healthy controls. However, further research is needed to explore the longitudinal relationship between sleep disruptions and QoL in early psychosis. Significant variations in how sleep is measured across studies highlight a need to assess disturbances to sleep using robust and consistent approaches in this patient group.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  At Risk Mental State; Psychosis; Sleep; Ultra high risk; Youth mental health

Year:  2020        PMID: 32646803     DOI: 10.1016/j.schres.2020.06.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  Sleep Disturbance in Individuals at Clinical High Risk for Psychosis.

Authors:  Nina Zaks; Tjasa Velikonja; Muhammad A Parvaz; Jamie Zinberg; Monica Done; Daniel H Mathalon; Jean Addington; Kristin Cadenhead; Tyrone Cannon; Barbara Cornblatt; Thomas McGlashan; Diana Perkins; William S Stone; Ming Tsuang; Elaine Walker; Scott W Woods; Matcheri S Keshavan; Daniel J Buysse; Eva Velthorst; Carrie E Bearden
Journal:  Schizophr Bull       Date:  2022-01-21       Impact factor: 7.348

2.  The relationship between stress responding in family context and stress sensitivity with sleep dysfunction in individuals at clinical high-risk for psychosis.

Authors:  Ivanka Ristanovic; Claudia M Haase; Jessica R Lunsford-Avery; Vijay A Mittal
Journal:  J Psychiatr Res       Date:  2022-03-02       Impact factor: 5.250

3.  Domains of Vulnerability, Resilience, Health Habits, and Mental and Physical Health for Health Disparities Research.

Authors:  Rebecca M Wolfe; Katie Beck-Felts; Brianna Speakar; William D Spaulding
Journal:  Behav Sci (Basel)       Date:  2022-07-18

4.  Self-compassion and sleep quality: Examining the mediating role of taking a proactive health focus and cognitive emotional regulation strategies.

Authors:  Brittany N Semenchuk; Samantha Onchulenko; Shaelyn M Strachan
Journal:  J Health Psychol       Date:  2021-09-20

Review 5.  The nature, consequences, mechanisms, and management of sleep disturbances in individuals at-risk for psychosis.

Authors:  Feten Fekih-Romdhane; Souheil Hallit; Majda Cheour; Haitham Jahrami
Journal:  Front Psychiatry       Date:  2022-09-20       Impact factor: 5.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.